Tregalizumab Completed Phase 2 Trials for House Dust Mite Allergy / Asthma, Allergic Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04673591Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients